Log in

NASDAQ:BCRXBioCryst Pharmaceuticals Stock Price, Forecast & News

$4.50
-0.54 (-10.72 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.48
Now: $4.50
$4.86
50-Day Range
$1.94
MA: $3.95
$5.61
52-Week Range
$1.38
Now: $4.50
$6.29
Volume17.37 million shs
Average Volume11.87 million shs
Market Capitalization$693.35 million
P/E RatioN/A
Dividend YieldN/A
Beta2.78
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More
BioCryst Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BCRX
CUSIP09058V10
Phone919-859-1302

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$48.83 million
Book Value$0.02 per share

Profitability

Net Income$-108,900,000.00
Net Margins-241.66%

Miscellaneous

Employees100
Market Cap$693.35 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

How has BioCryst Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

BioCryst Pharmaceuticals' stock was trading at $2.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BCRX stock has increased by 73.6% and is now trading at $4.4950. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioCryst Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioCryst Pharmaceuticals.

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for BioCryst Pharmaceuticals.

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($0.24) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.24). The biotechnology company had revenue of $4.82 million for the quarter, compared to the consensus estimate of $2.71 million. BioCryst Pharmaceuticals had a negative net margin of 241.66% and a negative return on equity of 4,223.68%. View BioCryst Pharmaceuticals' earnings history.

What price target have analysts set for BCRX?

5 equities research analysts have issued 1-year target prices for BioCryst Pharmaceuticals' stock. Their forecasts range from $4.00 to $13.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $7.60 in the next year. This suggests a possible upside of 69.1% from the stock's current price. View analysts' price targets for BioCryst Pharmaceuticals.

Has BioCryst Pharmaceuticals been receiving favorable news coverage?

News articles about BCRX stock have been trending very negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioCryst Pharmaceuticals earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutBioCryst Pharmaceuticals.

Who are some of BioCryst Pharmaceuticals' key competitors?

What other stocks do shareholders of BioCryst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo LoCo (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), La Jolla Pharmaceutical (LJPC), Virtu Financial (VIRT), Gilead Sciences (GILD), Opko Health (OPK), Exelixis (EXEL) and Novavax (NVAX).

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the following people:
  • Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 58)
  • Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 51)
  • Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 64)
  • Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 66)
  • Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 52)

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.68%), State Street Corp (3.72%), UBS Group AG (3.30%), Janus Henderson Group PLC (3.16%), Deutsche Bank AG (1.50%) and Geode Capital Management LLC (1.43%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Jon P Stonehouse, Kenneth B Lee Jr, Lynne Powell, Megan Sniecinski, Steve Aselage, Thomas R Staab II and William P Sheridan. View institutional ownership trends for BioCryst Pharmaceuticals.

Which major investors are selling BioCryst Pharmaceuticals stock?

BCRX stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Deutsche Bank AG, Sofinnova Investments Inc., Ghost Tree Capital LLC, Squarepoint Ops LLC, UBS Group AG, Two Sigma Investments LP, and JPMorgan Chase & Co.. View insider buying and selling activity for BioCryst Pharmaceuticals.

Which major investors are buying BioCryst Pharmaceuticals stock?

BCRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., Geode Capital Management LLC, State Street Corp, Acadian Asset Management LLC, Morgan Stanley, and Spark Investment Management LLC. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Alane P Barnes, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, and Steve Aselage. View insider buying and selling activity for BioCryst Pharmaceuticals.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $4.50.

How big of a company is BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has a market capitalization of $693.35 million and generates $48.83 million in revenue each year. The biotechnology company earns $-108,900,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. BioCryst Pharmaceuticals employs 100 workers across the globe.

What is BioCryst Pharmaceuticals' official website?

The official website for BioCryst Pharmaceuticals is www.biocryst.com.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.